Michael Freeman
Stock Analyst at Raymond James
(2.22)
# 2,770
Out of 5,182 analysts
6
Total ratings
60%
Success rate
8.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Freeman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Assumes: Outperform | $14 | $7.47 | +87.42% | 1 | Jun 11, 2025 | |
| TECX Tectonic Therapeutic | Reinstates: Outperform | $76 | $29.65 | +156.32% | 1 | Jun 11, 2025 | |
| DYN Dyne Therapeutics | Assumes: Outperform | $37 | $17.71 | +108.92% | 1 | Jun 11, 2025 | |
| IRON Disc Medicine | Reinstates: Strong Buy | $89 | $67.64 | +31.58% | 1 | Jun 11, 2025 | |
| RNA Atrium Therapeutics | Initiates: Strong Buy | $65 | $12.87 | +405.05% | 1 | Jun 11, 2025 | |
| BHC Bausch Health Companies | Initiates: Market Perform | $8 | $5.53 | +44.67% | 1 | Jul 10, 2024 |
Wave Life Sciences
Jun 11, 2025
Assumes: Outperform
Price Target: $14
Current: $7.47
Upside: +87.42%
Tectonic Therapeutic
Jun 11, 2025
Reinstates: Outperform
Price Target: $76
Current: $29.65
Upside: +156.32%
Dyne Therapeutics
Jun 11, 2025
Assumes: Outperform
Price Target: $37
Current: $17.71
Upside: +108.92%
Disc Medicine
Jun 11, 2025
Reinstates: Strong Buy
Price Target: $89
Current: $67.64
Upside: +31.58%
Atrium Therapeutics
Jun 11, 2025
Initiates: Strong Buy
Price Target: $65
Current: $12.87
Upside: +405.05%
Bausch Health Companies
Jul 10, 2024
Initiates: Market Perform
Price Target: $8
Current: $5.53
Upside: +44.67%